Stock Price For Teva Pharmaceuticals

I’ll help you create a blog post about the stock price for Teva Pharmaceuticals. I’ll first do a web search to gather the most recent and relevant information. Based on the search results, I’ll craft the blog post about Teva Pharmaceutical’s stock price:

Teva Pharmaceutical Industries has emerged as a compelling investment opportunity in 2026, with its stock price showing significant potential and attracting increased attention from analysts and investors. The company’s strategic positioning and recent financial performance offer an intriguing narrative for those tracking pharmaceutical stocks.

Current Stock Performance Snapshot

As of February 13, 2026, Teva Pharmaceutical Industries (NYSE: TEVA) is trading at $33.98, representing a modest 0.16% increase. The stock has demonstrated remarkable resilience, with some key performance metrics worth highlighting:

• 52-Week Low: $12.47
• 52-Week High: $37.34
• Current Market Capitalization: Approximately $37.23 billion
• Price-to-Earnings (P/E) Ratio: 54.10

Analyst Perspectives and Future Outlook

The investment community has shown growing optimism about Teva’s stock. Several prominent financial institutions have recently adjusted their perspectives:

• Jefferies raised the price target to $40, positioning Teva as a top 2026 investment idea
• Truist increased the price target to $36, highlighting the company's "affordable medicines" theme
• The current analyst consensus is a Buy rating, with 26 buy recommendations, 1 hold rating, and zero sell ratings

Financial Guidance and Expectations

Teva’s financial guidance for 2026 provides additional insights into the company’s projected performance:

• Earnings Per Share (EPS) Guidance: $2.570 - $2.770
• Revenue Guidance: $16.4 billion - $16.8 billion
• The company recently reported a quarterly EPS of $0.96, exceeding analyst expectations of $0.65

Strategic Positioning

Teva Pharmaceutical Industries continues to distinguish itself as a global pharmaceutical leader. The company specializes in developing, producing, and marketing generic pharmaceuticals and specialty branded medicines across multiple therapeutic areas, including:

• Central nervous system disorders
• Respiratory treatments
• Oncology
• Pain management
• Infectious disease medications

Investment Considerations

Potential investors should consider several key factors:

• The stock is currently trading 272.56% above its 52-week low
• Analysts' median price target is $27.74, with a high estimate of $45.00
• The company has demonstrated consistent growth, with sales increasing from $15.8 billion in 2023 to $17.46 billion in 2025

🔍 Note: While the stock shows promising indicators, investors should always conduct thorough personal research and consider their individual financial goals before making investment decisions.